Limits...
Efficacy of Bacillus clausii spores in the prevention of recurrent respiratory infections in children: a pilot study.

Marseglia GL, Tosca M, Cirillo I, Licari A, Leone M, Marseglia A, Castellazzi AM, Ciprandi G - Ther Clin Risk Manag (2007)

Bottom Line: Children treated with B. clausii had shorter duration of RI in comparison with the control group both during the treatment phase (mean 11.7 days vs 14.37; p=0.037) and the follow-up period (mean 6.6 days vs 10.92; p=0.049).This effect was evident also in allergic children during the follow-up.In conclusion, this pilot study provides the first preliminary evidence that B. clausii may exert a significant and persistent impact on RI in children and is safe and well tolerated.

View Article: PubMed Central - PubMed

ABSTRACT
Probiotic milk has been previously demonstrated to reduce the number of respiratory infections (RI) among children attending day care centres. Thus, this pilot study was aimed to assess the efficacy and the safety of 3 month treatment with Bacillus clausii in the prevention of recurrent respiratory infections (RRI) in children. Eighty children with RRI were studied: 40 of them were randomly treated with B. clausii for 3 months, and followed up for further 3 months; 40 were included in the control group during the same period. Children treated with B. clausii had shorter duration of RI in comparison with the control group both during the treatment phase (mean 11.7 days vs 14.37; p=0.037) and the follow-up period (mean 6.6 days vs 10.92; p=0.049). This effect was evident also in allergic children during the follow-up. In conclusion, this pilot study provides the first preliminary evidence that B. clausii may exert a significant and persistent impact on RI in children and is safe and well tolerated.

No MeSH data available.


Related in: MedlinePlus

Duration of RI (expressed as days in treated and nontreated as children with RRI during the treatment period (white column) and the follow-up (grey column).Abbreviations: RI, respiratory infections; RRI, recurrent respiratory infections.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC1936284&req=5

fig1: Duration of RI (expressed as days in treated and nontreated as children with RRI during the treatment period (white column) and the follow-up (grey column).Abbreviations: RI, respiratory infections; RRI, recurrent respiratory infections.

Mentions: Children treated with probiotic showed a significantly reduced duration (mean 11.7 ± 4.8 days) of RI in comparison with the control group (mean 14.37 ± 6.3) (p=0.037) as reported in Figure 1. The number of RI was less in the probiotic group (3.2 ± 0.8) compared with controls (3.9 ± 0.8). Regarding allergic children, the duration of RI was shorter in the probiotic group (13.44 ± 4.6) than in the nontreated controls (15.36 ± 7.4), as illustrated in Figure 2.


Efficacy of Bacillus clausii spores in the prevention of recurrent respiratory infections in children: a pilot study.

Marseglia GL, Tosca M, Cirillo I, Licari A, Leone M, Marseglia A, Castellazzi AM, Ciprandi G - Ther Clin Risk Manag (2007)

Duration of RI (expressed as days in treated and nontreated as children with RRI during the treatment period (white column) and the follow-up (grey column).Abbreviations: RI, respiratory infections; RRI, recurrent respiratory infections.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC1936284&req=5

fig1: Duration of RI (expressed as days in treated and nontreated as children with RRI during the treatment period (white column) and the follow-up (grey column).Abbreviations: RI, respiratory infections; RRI, recurrent respiratory infections.
Mentions: Children treated with probiotic showed a significantly reduced duration (mean 11.7 ± 4.8 days) of RI in comparison with the control group (mean 14.37 ± 6.3) (p=0.037) as reported in Figure 1. The number of RI was less in the probiotic group (3.2 ± 0.8) compared with controls (3.9 ± 0.8). Regarding allergic children, the duration of RI was shorter in the probiotic group (13.44 ± 4.6) than in the nontreated controls (15.36 ± 7.4), as illustrated in Figure 2.

Bottom Line: Children treated with B. clausii had shorter duration of RI in comparison with the control group both during the treatment phase (mean 11.7 days vs 14.37; p=0.037) and the follow-up period (mean 6.6 days vs 10.92; p=0.049).This effect was evident also in allergic children during the follow-up.In conclusion, this pilot study provides the first preliminary evidence that B. clausii may exert a significant and persistent impact on RI in children and is safe and well tolerated.

View Article: PubMed Central - PubMed

ABSTRACT
Probiotic milk has been previously demonstrated to reduce the number of respiratory infections (RI) among children attending day care centres. Thus, this pilot study was aimed to assess the efficacy and the safety of 3 month treatment with Bacillus clausii in the prevention of recurrent respiratory infections (RRI) in children. Eighty children with RRI were studied: 40 of them were randomly treated with B. clausii for 3 months, and followed up for further 3 months; 40 were included in the control group during the same period. Children treated with B. clausii had shorter duration of RI in comparison with the control group both during the treatment phase (mean 11.7 days vs 14.37; p=0.037) and the follow-up period (mean 6.6 days vs 10.92; p=0.049). This effect was evident also in allergic children during the follow-up. In conclusion, this pilot study provides the first preliminary evidence that B. clausii may exert a significant and persistent impact on RI in children and is safe and well tolerated.

No MeSH data available.


Related in: MedlinePlus